Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Treatment of infantile-onset Pompe disease in a rat model with muscle-directed AAV gene therapy

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Bertolín Gálvez, Joan|||0000-0002-5196-0955
  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jaén Sitges, Maria Luisa|||0000-0002-9188-0810
  • Garcia, Miquel|||0000-0002-1602-4993
  • Pujol i Altarriba, Anna|||0000-0002-3484-598X
  • Vilà, Laia|||0000-0002-1211-5804
  • Sacristan, Victor|||0000-0003-0356-0356
  • Barbon, Elena
  • Ronzitti, Giuseppe
  • Andari, Jihad El
  • Tulalamba, Warut
  • Pham, Quang Hong
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • VandenDriessche, Thierry
  • Chuah, Marinee K.
  • Grimm, Dirk
  • Mingozzi, Federico
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Objective: Pompe disease (PD) is caused by deficiency of the lysosomal enzyme acid α-glucosidase (GAA), leading to progressive glycogen accumulation and severe myopathy with progressive muscle weakness. In the Infantile-Onset PD (IOPD), death generally occurs <1 year of age. There is no cure for IOPD. Mouse models of PD do not completely reproduce human IOPD severity. Our main objective was to generate the first IOPD rat model to assess an innovative muscle-directed adeno-associated viral (AAV) vector-mediated gene therapy. Methods: PD rats were generated by CRISPR/Cas9 technology. The novel highly myotropic bioengineered capsid AAVMYO3 and an optimized muscle-specific promoter in conjunction with a transcriptional cis-regulatory element were used to achieve robust Gaa expression in the entire muscular system. Several metabolic, molecular, histopathological, and functional parameters were measured. Results: PD rats showed early-onset widespread glycogen accumulation, hepato- and cardiomegaly, decreased body and tissue weight, severe impaired muscle function and decreased survival, closely resembling human IOPD. Treatment with AAVMYO3-Gaa vectors resulted in widespread expression of Gaa in muscle throughout the body, normalizing glycogen storage pathology, restoring muscle mass and strength, counteracting cardiomegaly and normalizing survival rate. Conclusions: This gene therapy holds great potential to treat glycogen metabolism alterations in IOPD. Moreover, the AAV-mediated approach may be exploited for other inherited muscle diseases, which also are limited by the inefficient widespread delivery of therapeutic transgenes throughout the muscular system.
Repisalud
Publication Artículo científico (JournalArticle)

Rescue of Advanced Pompe Disease in Mice with Hepatic Expression of Secretable Acid α-Glucosidase.

  • Cagin, Umut
  • Puzzo, Francesco
  • Gomez, Manuel J
  • Moya-Nilges, Maryse
  • Sellier, Pauline
  • Abad, Catalina
  • van Wittenberghe, Laetitia
  • Daniele, Nathalie
  • Guerchet, Nicolas
  • Gjata, Bernard
  • Collaud, Fanny
  • Charles, Severine
  • Sola, Marcelo Simon
  • Boyer, Olivier
  • Krijnse-Locker, Jacomina
  • Ronzitti, Giuseppe
  • Colella, Pasqualina
  • Mingozzi, Federico
Pompe disease is a neuromuscular disorder caused by disease-associated variants in the gene encoding for the lysosomal enzyme acid α-glucosidase (GAA), which converts lysosomal glycogen to glucose. We previously reported full rescue of Pompe disease in symptomatic 4-month-old Gaa knockout (Gaa-/-) mice by adeno-associated virus (AAV) vector-mediated liver gene transfer of an engineered secretable form of GAA (secGAA). Here, we showed that hepatic expression of secGAA rescues the phenotype of 4-month-old Gaa-/- mice at vector doses at which the native form of GAA has little to no therapeutic effect. Based on these results, we then treated severely affected 9-month-old Gaa-/- mice with an AAV vector expressing secGAA and followed the animals for 9 months thereafter. AAV-treated Gaa-/- mice showed complete reversal of the Pompe phenotype, with rescue of glycogen accumulation in most tissues, including the central nervous system, and normalization of muscle strength. Transcriptomic profiling of skeletal muscle showed rescue of most altered pathways, including those involved in mitochondrial defects, a finding supported by structural and biochemical analyses, which also showed restoration of lysosomal function. Together, these results provide insight into the reversibility of advanced Pompe disease in the Gaa-/- mouse model via liver gene transfer of secGAA.
Repisalud
Publication Artículo científico (JournalArticle)

Gene therapy with secreted acid alpha-glucosidase rescues Pompe disease in a novel mouse model with early-onset spinal cord and respiratory defects.

  • Colella, Pasqualina
  • Sellier, Pauline
  • Gomez, Manuel J
  • Biferi, Maria G
  • Tanniou, Guillaume
  • Guerchet, Nicolas
  • Cohen-Tannoudji, Mathilde
  • Moya-Nilges, Maryse
  • van Wittenberghe, Laetitia
  • Daniele, Natalie
  • Gjata, Bernard
  • Krijnse-Locker, Jacomina
  • Collaud, Fanny
  • Simon-Sola, Marcelo
  • Charles, Severine
  • Cagin, Umut
  • Mingozzi, Federico
Pompe disease (PD) is a neuromuscular disorder caused by deficiency of acidalpha-glucosidase (GAA), leading to motor and respiratory dysfunctions. Available Gaa knock-out (KO) mouse models do not accurately mimic PD, particularly its highly impaired respiratory phenotype. Here we developed a new mouse model of PD crossing Gaa KOB6;129 with DBA2/J mice. We subsequently treated Gaa KODBA2/J mice with adeno-associated virus (AAV) vectors expressing a secretable form of GAA (secGAA). Male Gaa KODBA2/J mice present most of the key features of the human disease, including early lethality, severe respiratory impairment, cardiac hypertrophy and muscle weakness. Transcriptome analyses of Gaa KODBA2/J, compared to the parental Gaa KOB6;129 mice, revealed a profoundly impaired gene signature in the spinal cord and a similarly deregulated gene expression in skeletal muscle. Muscle and spinal cord transcriptome changes, biochemical defects, respiratory and muscle function in the Gaa KODBA2/J model were significantly improved upon gene therapy with AAV vectors expressing secGAA. These data show that the genetic background impacts on the severity of respiratory function and neuroglial spinal cord defects in the Gaa KO mouse model of PD. Our findings have implications for PD prognosis and treatment, show novel molecular pathophysiology mechanisms of the disease and provide a unique model to study PD respiratory defects, which majorly affect patients. This work was supported by Genethon, the French Muscular Dystrophy Association (AFM), the European Commission (grant nos. 667751, 617432, and 797144), and Spark Therapeutics.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

FGF21 gene therapy as treatment for obesity and insulin resistance

  • Jimenez, Veronica|||0000-0001-9145-9877
  • Jambrina Pallarés, Claudia|||0000-0002-9093-5568
  • Casaña Lorente, Estefania|||0000-0002-1353-5018
  • Sacristan, Victor|||0000-0003-0356-0356
  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Darriba, Sara
  • Rodó Morera, Jordi|||0000-0001-8533-2597
  • Mallol, Cristina|||0000-0002-2920-9612
  • Garcia, Miquel|||0000-0002-1602-4993
  • León, Xavier|||0000-0002-8393-2721
  • Marcó, Sara|||0000-0003-3502-5198
  • Ribera Sánchez, Albert|||0000-0002-7120-4276
  • Elias Puigdomenech, Ivet|||0000-0002-1304-9597
  • Casellas Comallonga, Alba|||0000-0003-0203-4733
  • Grass Costa, Ignasi|||0000-0002-6917-3271
  • Elias Bosch, Gemma|||0000-0003-1985-7955
  • Ferre, Tura|||0000-0001-9713-0829
  • Motas, Sandra|||0000-0003-2748-5952
  • Franckhauser, Sylvie|||0000-0001-5255-1224
  • Mulero, Francisca|||0000-0001-9584-4211
  • Navarro Beltrán, Marc|||0000-0002-9678-6129
  • Haurigot Mendonça, Virginia|||0000-0002-9772-2565
  • Ruberte Paris, Jesús|||0000-0003-1540-1432
  • Bosch i Tubert, Fàtima|||0000-0002-7705-5515
Prevalence of type 2 diabetes (T2D) and obesity is increasing worldwide. Currently available therapies are not suited for all patients in the heterogeneous obese/T2D population, hence the need for novel treatments. Fibroblast growth factor 21 (21) is considered a promising therapeutic agent for T2D/obesity. Native 21 has, however, poor pharmacokinetic properties, making gene therapy an attractive strategy to achieve sustained circulating levels of this protein. Here, adeno-associated viral vectors () were used to genetically engineer liver, adipose tissue, or skeletal muscle to secrete 21. Treatment of animals under long-term high-fat diet feeding or of ob/ob mice resulted in marked reductions in body weight, adipose tissue hypertrophy and inflammation, hepatic steatosis, inflammation and fibrosis, and insulin resistance for.